Contributed by Steven Miller, Vice President of Pharmacy and Education for 340B Health

For those who may not follow the 340B drug pricing program closely, what is the 340B rebate issue and why is it receiving so much attention?
The 340B drug pricing program has always been built on upfront discounts. Hospitals and other covered entities purchase outpatient drugs at reduced prices, and those savings help support care for patients with low incomes and those in rural communities.

The rebate issue involves proposals to replace that structure with a backend system. Under a rebate model, hospitals would buy drugs at full price — wholesale acquisition cost — and then submit claims data to drug companies after dispensing. The drugmakers would review those claims and decide on their own whether they qualify for rebates and when they would make those payments.

This has drawn significant attention because it would fundamentally change how the program has operated for more than 30 years. Instead of predictable savings at the point of purchase, hospitals would need to front the full cost of drugs and rely on a retrospective process that introduces uncertainty, delays, and financial risk into what has historically been a stable framework.

What are the key recent developments at the federal level?
The biggest development has been the halt of a federal rebate pilot that the Health Resources & Services Administration (HRSA) had approved for certain pharmaceutical companies manufacturing drugs that are subject to new Medicare Part D price caps. A federal court issued a preliminary injunction blocking the pilot, finding that the agency likely failed to properly consider significant administrative and financial costs the program would impose on covered entities.

After that decision, the government attempted to move forward with the pilot during the appeals process but was unsuccessful and ultimately dismissed its appeal. The administration has indicated it will not proceed with that specific pilot as approved, which was a significant development for hospitals concerned about the immediate impact of rebates.

At the same time, the agency has indicated it is pursuing an even broader rebate program through a new process. It issued both a request for information and a separate data collection proposal to solicit stakeholder feedback on how such a rebate model might work and what burdens it would create. So 340B rebates could soon resurface in a different form and in a bigger way.

What would a rebate model mean for hospital pharmacy operations?
340B rebates would introduce both financial and administrative challenges that represent a major shift from current practice. Today, 340B hospitals and pharmacies can acquire drugs at 340B prices and operate with a clear understanding of acquisition costs. That predictability supports budgeting, inventory management, and program oversight activities.

Under a rebate model, hospitals would need to purchase drugs at full price and carry those costs while waiting for reimbursement. For high-cost therapies, that could require significant working capital and create real cash-flow pressures, particularly for hospitals that already operate on thin margins.

There also would be new administrative demands layered on top of existing responsibilities. Hospitals would need to collect and submit detailed claims data to each drugmaker, track submissions across multiple platforms, reconcile payments, and investigate discrepancies. Each company could have different requirements, timelines, and validation processes, which adds complexity and increases the likelihood of errors.
On top of that, hospitals would need processes for handling denied or delayed rebates. That could involve additional staff time, new technology investments, and closer coordination across pharmacy, finance, and compliance teams.

Why are hospitals particularly concerned about rebate denials and delays?
A key issue is that drug companies would have substantial control over determining which claims qualify for rebates and how quickly they pay those rebates. Even if HRSA were to establish rules about this process, a retrospective system creates more room for interpretation and variation.

Hospitals are concerned that drugmakers could apply restrictive criteria or deny claims that would be considered eligible under the current upfront model. Even when hospitals believe they are fully compliant, they could face delays in payment or outright denials that require follow-up and appeals.

That uncertainty makes it difficult to project savings and manage operations effectively. It also raises the risk that the overall value of 340B to hospitals and their patients could decline, not just because of denials but because of the added administrative costs required to pursue and reconcile rebates.

How could these changes affect patient care?
The financial and operational pressures associated with rebates could have direct and indirect effects on patients. Many hospitals rely on 340B savings to fund programs such as medication assistance, outpatient clinics, care coordination, and other services that improve access and outcomes.

If those savings become less predictable or are reduced due to delays, denials, or administrative costs, hospitals will have fewer resources to invest in those services. That could affect patients who depend on those programs, particularly those with low incomes, chronic conditions, or limited access to care.

Even the need to carry higher drug costs for a period can strain hospital budgets. Over time, those pressures can influence decisions about staffing, services, and investments in patient care.

How does this issue connect to other recent drug pricing changes?
The rebate discussion is happening alongside other major policy changes, including Medicare drug price caps authorized by the Inflation Reduction Act (IRA). Those caps affect 340B savings for certain drugs, particularly in Medicare Part D, and are already prompting changes in drugmaker pricing strategies.

The halted rebate pilot was tied in part to those price caps. But layering a rebate model on top of those changes would add complexity for hospitals that are already trying to understand how their savings will be affected.
Pharmacy teams need to be aware of both developments, as they will shape financial planning, contracting strategies, and operational decisions in the coming years.

What have 340B hospitals been doing in response?
340B hospitals have been actively engaging with federal policymakers and regulators to share their concerns. Hospitals have submitted detailed comments opposing the use of rebates, focusing on the financial, operational, and patient care impacts and explaining why a shift away from upfront discounts would be harmful.
In addition, hospitals have supported legal efforts that led to the court blocking the initial rebate pilot, which provided important — though potentially temporary — relief.

The hospitals’ goal has been to ensure that policymakers fully understand how critical the current structure is and what is at stake for hospitals and the patients they serve.

What should pharmacy leaders be doing now?
Even with uncertainty about future policy decisions, pharmacy leaders can take practical steps to prepare. That includes evaluating whether their current systems can capture the level of detail that a rebate model would require and identifying gaps in data collection and reporting.

They also should engage with internal stakeholders, including finance, compliance, and information technology teams, to understand the operational and resource implications of a potential shift. Mapping out potential workflows in advance can help reduce disruption if such changes move forward.

Just as important, pharmacy leaders should stay informed and engaged in policy discussions. Their operational perspective is essential to ensuring that any 340B changes policymakers are contemplating are workable and do not inadvertently disrupt patient care.

What is your bottom-line message for pharmacy professionals?
The rebate issue is not just a policy debate — it has direct implications for how hospital pharmacies operate and how patients access care. The current upfront discount model provides stability and predictability that hospitals rely on to serve their communities and plan for the future.

Moving to a rebate model would shift financial risk and administrative burden onto providers while introducing uncertainty into the system. That is why it is important for pharmacy professionals to understand what is at stake, think through the operational implications, and stay engaged as the discussion continues.

As this issue evolves, informed and active participation from the pharmacy community will be critical to ensuring the 340B drug pricing program continues to function in a way that supports both providers and patients.

Steven Miller is the vice president of pharmacy and education for 340B Health, a nonprofit organization representing more than 1,600 hospitals and health systems participating in the federal 340Bdrug pricing program.